Your new experience awaits. Try the new design now and help us make it even better

PERSPECTIVE article

Front. Artif. Intell.

Sec. Medicine and Public Health

Volume 8 - 2025 | doi: 10.3389/frai.2025.1698717

Medicine for Artificial Intelligence (MAI): Applying a Medical Framework to AI Anomalies

Provisionally accepted
  • 1Tokyo Daigaku, Bunkyo, Japan
  • 2Jawaharlal Nehru University School of Biotechnology, New Delhi, India

The final, formatted version of the article will be published soon.

We propose Medicine for Artificial Intelligence (MAI), a clinical framework that reconceptualizes AI anomalies as diseases requiring systematic screening, differential diagnosis, treatment, and follow-up. Contemporary discourse on failures (e.g., "hallucination") is ad hoc and fragmented across domains, impeding cumulative knowledge and reproducible management. MAI adapts medical nosology to AI by formalizing core constructs—disease, symptom, diagnosis, treatment, and classification—and mapping a clinical workflow (examination → diagnosis → intervention) onto the AI lifecycle. As a proof-of-concept, we developed DSA-1, a prototype taxonomy of 45 disorders across nine functional chapters. This approach clarifies ambiguous failure modes (e.g., distinguishing hallucination subtypes), links diagnoses to actionable interventions and evaluation metrics, and supports lifecycle practices, including triage and "AI health checks." MAI further maps epidemiology, severity, and detectability to risk-assessment constructs, complementing top-down governance with bottom-up technical resolution. By aligning clinical methodology with AI engineering and coordinating researchers, clinicians, and regulators, MAI offers a reproducible foundation for safer, more resilient, and auditable AI systems.

Keywords: AI anomaly1, Classification2, medical analogy3, failure taxonomy4, risk assessment5

Received: 04 Sep 2025; Accepted: 25 Sep 2025.

Copyright: © 2025 Kato, Komura, Panda and Ishikawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shumpei Ishikawa, ishum-prm@m.u-tokyo.ac.jp

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.